Thanks for those questions. I would say both of those fall more in the sales and marketing category, so I'm going to ask Dr. Jeffs, our President, to kindly address those.
Roger A. Jeffs
That you, Martine. The way, as we said before, that there is quarter-to-quarter fluctuation in ordering patterns from our main customers, which are the specialty pharmacies. And I think this quarter is reflective of normal variations within quarters.
When we look going forward into 2012, we see the majority of the growth coming from Tyvaso and Adcirca in terms of incremental revenue addition. However, the core base of Remodulin revenue, we expect to remain stable and grow slightly as well. So we think there should be growth within the full suite of products that we sell and we remain confident on guidance for 2012 at the 875 range as previously stated.
Thanks, Roger. Thank you, questioner from Collin Stewart. Operator, could you please open the line to the next question.
Absolutely. Our next question comes from the line of Liana Moussatos from Wedbush Securities. Your line is now open, please go ahead.
Liana Moussatos - Wedbush Securities Inc.
Thank you for taking my question. Can you give us the geographic breakdown of Remodulin sales, Europe and U.S.?
Thanks Liana, nice to hear your voice this morning. I think it probably would be more in John Ferrari's category to give the breakdown of revenues ex-U.S. and U.S. So John could you please help with that question?
John M. Ferrari
I'd be happy to. We haven't seen any significant fluctuation between U.S. and non-U.S. sales for Remodulin that we reported over the years, so somewhere between 13 and 15% of our Remodulin revenues come the rest of the world or outside the U.S.
Thanks, John. Thanks, Liana. Operator, can you please take the next question?
Read the rest of this transcript for free on seekingalpha.com